RSV jab reduced infant hospital admissions by 83%, study reports
Latest Information and Opinions: Study Shows RSV Vaccine Decreased Infant Hospitalizations by 83%
The article titled "News BMJ 2023; 383 doi: https://doi.org/10.1136/bmj.p2988 (Published 28 December 2023) Cite this as: BMJ 2023;383:p2988" has been released, according to sources. This publication can be cited as BMJ 2023;383:p2988.
According to a recent study, the medication known as Beyfortus, which is a long-lasting monoclonal antibody, decreased the number of hospitalizations caused by the respiratory syncytial virus in infants by 83%.
A study was conducted in France, Germany, and the UK that involved over 8000 babies who were twelve months old or younger. The participants were randomly given either nirsevimab (4037 babies) or standard care (4021 babies received no intervention) in preparation for their first RSV season in September and October 2022.
A research project, which received financial backing from Sanofi and AstraZeneca pharmaceutical companies, has uncovered that out of the infants included in the study, 0.3% of those in the nirsevimab group experienced an adverse event compared to 1.5% in the standard group.
